3D 바이오프린팅 시장 : 제품별(바이오프린터, 바이오잉크, 재료, 소프트웨어, 액세서리), 용도별(암 연구, 조직공학, Drug Discovery), 최종사용자별 - 세계 예측(-2030년)

3D Bioprinting Market by Product (Bioprinter, Bioinks, Materials [Hydrogels, Cells, Biomaterials], Software), Technology (Inkjet, Extrusion, Laser, SLS), Application (Cancer Research, Tissue Engineering, Drug Discovery), End User-Global Forecast to 2030.

The 3D bioprinting market is projected to reach $5.21 billion by 2030 at a CAGR of 17.1% from 2024 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. This growth is due to the technological advancements in 3D bioprinting, the rising geriatric population coupled with the growing burden of chronic diseases, and increasing R&D investments. However, the lack of skilled professionals and high costs associated with 3D bioprinting restrain the growth of this market.

Furthermore, the increasing demand for organ transplantation is expected to generate growth opportunities for the players operating in this market. However, concerns regarding intellectual property rights and safety issues associated with the use of 3D bioprinted products are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the 3D bioprinting market are Organovo Holdings Inc. (U.S.), BICO Group AB (Sweden), Aspect Biosystems Ltd. (Canada), Cyfuse Biomedical K.K. (Japan), Advanced Solutions Life Sciences, LLC (U.S.), CollPlant Biotechnologies Ltd. (Israel), regenHU Ltd. (Switzerland), Poietis (France), REGEMAT 3D, SL (Spain), 3DBio Therapeutics (U.S.), and Foldink Life Science Technologies (Armenia).

Among all the products studied in this report, in 2024, the bioprinters segment is expected to account for the largest share of the 3D Bioprinting market. 3D bioprinters produce tissues and organ patches from a patient's cell, which can reduce the chance of rejection, create patient-specific treatment, and reduce the need for animal testing. Further, technological advancements in bioprinters help researchers to focus on various applications and save time and money developing an internal system are the factors that contribute to the large market share of this segment in the 3D bioprinting market.

Among all the applications studied in this report, in 2024, the cancer research segment is expected to account for the largest share of the 3D bioprinting market. The large market share of this segment is attributed to the rising prevalence of cancer. According to GLOBOCAN, in 2020, 19.3 million cancer cases were diagnosed all over the world. The number of cases is expected to increase to 24.5 million by 2030. Cancer models that replicate the tumor microenvironment are produced using 3D bioprinting. This may assist with cancer medication screening and contribute to a greater understanding of cancer.

Among all the end users studied in this report, in 2024, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the 3D Bioprinting market. The large market share of this segment is attributed to the substantial investments in R&D made by pharmaceutical and biotechnology companies to introduce innovative therapies and treatments. According to the Congressional Budget Office data published in April 2021, the pharmaceutical industry spent USD 83 billion on research and development in 2019, highlighting the significant investment in this field.

An in-depth analysis of the geographical scenario of the 3D bioprinting market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the 3D bioprinting market. In the region in 2024, the U.S. is expected to account for the largest share of the 3D Bioprinting market in North America. The large share of this regional market is attributed to the rapid adoption of 3D bioprinters in various cancer research studies, advanced research infrastructure, and availability of funding to support life science research.

Scope of the Report:

3D Bioprinting Market Assessment-by Product

• Bioprinters
  • Inkjet-based
  • Extrusion-based
  • Stereolithography (SLA)
  • Laser-based
  • Fused-deposition Modeling (FDM)
  • Selective Laser Sintering (SLS)
  • Other Technologies
• Bioinks
  • Natural
  • Synthetic
  • Hybrid
• Materials
  • Hydrogels
  • Living Cells
  • Extracellular Matrices
  • Biomaterials
  • Other Materials
• Software
• Accessories and Consumables

(Note 1: Other technologies include Digital Light Processing (DLP), Injection pore filling (IPF), and Injection volume filling (IVF)

Note 2: Other materials include synthetic polymers, composites, and nanocellulose.)

3D Bioprinting Market Assessment-by Application

• Cancer Research
• Regenerative Medicines
• Drug Discovery and Testing
• Tissue Engineering
• Biomaterials and cells research
• Other Applications

Note: Other applications include organ transplantation, tissue, and disease modeling.

3D Bioprinting Market Assessment-by End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations (CROs)

3D Bioprinting Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
• 2.3. Market Sizing and Forecasting
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Drivers
  • 4.2.1. Technological Advancements in 3D Bioprinting
  • 4.2.2. Rising Geriatric Population, Coupled with the Growing Burden of Chronic Diseases
  • 4.2.3. Increasing R&D Investments
• 4.3. Restraints
  • 4.3.1. Lack of Skilled Professionals
  • 4.3.2. High Costs Associated with 3D Bioprinting
• 4.4. Opportunities
  • 4.4.1. Increasing Demand for Organ Transplantation
• 4.5. Challenges
  • 4.5.1. Concerns Regarding Intellectual Property Rights
  • 4.5.2. Safety Issues Associated With the Use of 3D Bioprinted Products
• 4.6. Factor Analysis
• 4.7. Pricing Analysis
• 4.8. Technology Trends
• 4.9. Regulatory Analysis
• 4.10. Porter's Five Forces Analysis

5. 3D Bioprinting Market Assessment-by Product

• 5.1. Overview
• 5.2. Bioprinters
  • 5.2.1. Inkjet-based
  • 5.2.2. Extrusion-based
  • 5.2.3. Stereolithography (SLA)
  • 5.2.4. Laser-based
  • 5.2.5. Fused-deposition modeling (FDM)
  • 5.2.6. Selective laser sintering (SLS)
  • 5.2.7. Other Technologies
• 5.3. Bioinks
  • 5.3.1. Natural
  • 5.3.2. Synthetic
  • 5.3.3. Hybrid
• 5.4. Materials
  • 5.4.1. Hydrogels
  • 5.4.2. Living Cells
  • 5.4.3. Extracellular Matrices
  • 5.4.4. Biomaterials
  • 5.4.5. Other Materials
• 5.5. Software
• 5.6. Accessories and Consumables

6. 3D Bioprinting Assessment-by Application

• 6.1. Overview
• 6.2. Cancer Research
• 6.3. Regenerative Medicines
• 6.4. Drug Discovery and Testing
• 6.5. Tissue Engineering
• 6.6. Biomaterials and cells research
• 6.7. Other Applications

7. 3D Bioprinting Assessment-by End User

• 7.1. Overview
• 7.2. Pharmaceutical and Biotechnology Companies
• 7.3. Academic and Research Institutes
• 7.4. Contract Research Organizations (CROs)

8. 3D Bioprinting Market Assessment-by Geography

• 8.1. Overview
• 8.2. North America
  • 8.2.1. U.S.
  • 8.2.2. Canada
• 8.3. Europe
  • 8.3.1. Germany
  • 8.3.2. France
  • 8.3.3. U.K.
  • 8.3.4. Italy
  • 8.3.5. Spain
  • 8.3.6. Belgium
  • 8.3.7. Switzerland
  • 8.3.8. Netherlands
  • 8.3.9. Rest of Europe
• 8.4. Asia-Pacific
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. South Korea
  • 8.4.6. Rest of Asia-Pacific
• 8.5. Latin America
  • 8.5.1. Brazil
  • 8.5.2. Mexico
  • 8.5.3. Rest of Latin America
• 8.6. Middle East & Africa

9. Competition Analysis

• 9.1. Overview
• 9.2. Key Growth Strategies
• 9.3. Competitive Benchmarking
• 9.4. Competitive Dashboard
  • 9.4.1. Industry Leaders
  • 9.4.2. Market Differentiators
  • 9.4.3. Vanguards
  • 9.4.4. Emerging Companies
• 9.5. Market Share Analysis/Market Rankings, by Key Players (2022)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments, and SWOT Analysis*)

• 10.1. Organovo Holdings Inc.
• 10.2. BICO Group AB
• 10.3. Aspect Biosystems Ltd.
• 10.4. Cyfuse Biomedical K.K.
• 10.5. Advanced Solutions Life Sciences, LLC
• 10.6. CollPlant Biotechnologies Ltd.
• 10.7. regenHU Ltd.
• 10.8. Poietis
• 10.9. REGEMAT 3D, SL
• 10.10. 3D Bioprinting Solutions
• 10.11. Foldink Life Science Technologies

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

11. Appendix

• 11.1. Available Customization
• 11.2. Related Reports